Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials

Jason Grebely, Gregory J. Dore, Stefan Zeuzem, Richard J. Aspinall, Raymond Fox, Lingling Han, John McNally, Anu Osinusi, Diana M. Brainard, G. Mani Subramanian, Macky Natha, Graham R. Foster, Alessandra Mangia, Mark Sulkowski, Jordan J. Feld

Research output: Contribution to journalArticle

Abstract

In this analysis of the ASTRAL trials (non-opioid substitution therapy [OST], n = 984; OST, n = 51) evaluating the once-daily, pan-genotypic regimen of sofosbuvir/velpatasvir for hepatitis C virus infection, OST did not impact completion, adherence, sustained virologic response (SVR12), or safety. SVR12 was 96% (95% confidence interval, 87%, >99%) in those receiving OST.

Original languageEnglish (US)
Pages (from-to)1479-1481
Number of pages3
JournalClinical Infectious Diseases
Volume63
Issue number11
DOIs
StatePublished - Jan 1 2016

Keywords

  • HCV
  • OST
  • PWID
  • Sofosbuvir
  • Velpatasvir

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials'. Together they form a unique fingerprint.

  • Cite this

    Grebely, J., Dore, G. J., Zeuzem, S., Aspinall, R. J., Fox, R., Han, L., McNally, J., Osinusi, A., Brainard, D. M., Subramanian, G. M., Natha, M., Foster, G. R., Mangia, A., Sulkowski, M., & Feld, J. J. (2016). Efficacy and safety of sofosbuvir/velpatasvir in patients with chronic hepatitis C virus infection receiving opioid substitution therapy: Analysis of phase 3 ASTRAL trials. Clinical Infectious Diseases, 63(11), 1479-1481. https://doi.org/10.1093/cid/ciw579